Kane Biotech announced a net loss of $2.7 million for 2025, an improvement from a $3.16 million loss in 2024, driven by restructuring and cost reductions. The company is shifting focus to expanding its revyve antimicrobial wound care product line in the US and Canada through clinical studies, new distribution agreements, and regulatory approvals. Kane secured multiple private placements totaling over $3 million and received FDA clearance for new revyve products. In 2026, Kane aims to grow its distributor network, continue clinical trials, and develop new wound care products to drive sustainable revenue growth.
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
The US will impose a 25% tariff on most imports from Brazil starting July 22, following a yearlong investigation into alleged unfair trade practices by Brazil. The tariffs target issues such as Brazil's demands on US tech firms to remove political co...
